

Johnson & Johnson

1 ? . Ž ((f \$ L & \$ + - , - ' \$, %
 B 5 . Ž % * (* , - * ' ' \$ *)
 5 1 Ž * % & ' - & , \$ \$ + \$ \$ \$
 U W j c b 4 d f c U W j j Y j b j Y g h c f g " V e a

13:13 13 Oct 2020

Johnson & Johnson second on the list of COVID-19 vaccine setbacks, markets remain calm

Johnson & Johnson (NYSE:JNJ) is the second major company to have encountered a setback in developing a COVID-19 vaccine candidate.

The firm paused dosing in all clinical trials after an unexplained illness in a study participant, though it is unclear whether the individual received a study treatment or a placebo.

READ: Johnson & Johnson halts COVID-19 vaccine trials after unexplained illness

The pharma giant stressed such adverse events are an expected part of any clinical study, especially large studies and there will be a careful review of all medical information before deciding whether to restart trials.

It noted that a study pause, which is initiated by the study sponsor and not normally communicated to the public, is not the same as a regulatory hold of a clinical trial, which is required by a health authority.

"The news that Johnson & Johnson has paused its vaccine trial has not gone entirely unnoticed, but the market has learned to live with the ups and downs of product development over the past few months, with the reaction to this kind of news much more muted than during the summer," said Chris Beauchamp, chief market analyst at IG.

Investors are still hoping it remains a short-lived incident as it happened to AstraZeneca PLC (LON:AZN), which stopped trials for the Oxford University vaccine in early September after a UK volunteer reported transverse myelitis, an inflammation of the spinal cord that can cause paralysis.

While this pause was widely reported as soon as it happened, a first halt in July went under the radar when another UK patient showed similar symptoms, although they were attributed to the fact that she was already suffering from multiple sclerosis.

The trials later resumed in the UK, India, South Africa and Brazil but are still on hold in the US, where regulations are tougher.

J&J's trial is involving up to 60,000 participants in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the US. They are all at least 18 years old including significant representation from those that are over age 60.


If approved, the jab would be available for emergency use authorisation in early 2021 on a not-for-profit basis.

At the moment, the most advanced candidates are the one developed jointly by Pfizer Inc. (NYSE:PFE) and BioNTech (NASDAQ: BNTX), which they hope will begin regulatory scrutiny in October, and Moderna, which said last week it would soon apply for real-time reviews of its candidate in the EU.

Price: 162.38

Market Cap: \$427.47 billion

1 Year Share Price Graph



Share Information

Code: JNJ

Listing: NYSE

52 week High Low
164.085 109.17

Sector: Medical technology & services

Website: www.jnj.com

Company Synopsis:

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

action@proactiveinvestors.com

While these jabs would require two doses, J&J's is designed for one.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.